A Phase 2, Randomized, Double-Blind, Multiple-Dose, Placebo-Controlled Study to Evaluate the Safety and Efficacy of BIIB104 in Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS)
Phase of Trial: Phase II
Latest Information Update: 07 Nov 2019
Price : $35 *
At a glance
- Drugs BIIB 104 (Primary)
- Indications Cognition disorders
- Focus Therapeutic Use
- Acronyms TALLY
- Sponsors Biogen
- 15 Nov 2018 Status changed from planning to recruiting.
- 16 Mar 2018 New trial record
- 12 Mar 2018 According to the Biogen media release, company plans to initiate this trial in the second half of 2018.